110 related articles for article (PubMed ID: 20647701)
1. [Oral molecular targeting agents in hematological malignancy].
Wakabayashi S; Ohashi K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1214-8. PubMed ID: 20647701
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in chronic myeloid leukemia.
Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induced by molecular targeting therapy in hematological malignancies.
Adachi S; Leoni LM; Carson DA; Nakahata T
Acta Haematol; 2004; 111(1-2):107-23. PubMed ID: 14646349
[TBL] [Abstract][Full Text] [Related]
4. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
5. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
6. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Tallman MS
Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
[TBL] [Abstract][Full Text] [Related]
7. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
le Coutre P; Schwarz M; Kim TD
Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
[TBL] [Abstract][Full Text] [Related]
8. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. Treatment options in imatinib-resistant chronic myelogenous leukemia.
Marshall HM; Hammond JM
Ann Pharmacother; 2008 Feb; 42(2):259-64. PubMed ID: 18212257
[TBL] [Abstract][Full Text] [Related]
11. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
Cang S; Liu D
J Hematol Oncol; 2008 Oct; 1():15. PubMed ID: 18828913
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
14. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets and the treatment of myeloid leukemia.
Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
17. Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia.
Wujcik D
Oncol Nurs Forum; 1996 Apr; 23(3):478-87. PubMed ID: 8801508
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
19. ENMD-2076 for hematological malignancies.
How J; Yee K
Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic approach for hematological malignancies based on cellular differentiation and apoptosis.
Kizaki M; Nakazato T; Ito K; Kawamura C; Miyakawa Y; Ikeda Y
Int J Hematol; 2002 Aug; 76 Suppl 1():250-2. PubMed ID: 12430859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]